| 1 |
33283357 | Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network. | 2021 Feb |
1 |
| 2 |
34795257 | Defactinib inhibits PYK2 phosphorylation of IRF5 and reduces intestinal inflammation. | 2021 Nov 18 |
2 |
| 3 |
27025608 | A first-in-Asian phase 1 study to evaluate safety, pharmacokinetics and clinical activity of VS-6063, a focal adhesion kinase (FAK) inhibitor in Japanese patients with advanced solid tumors. | 2016 May |
2 |
| 4 |
26334219 | A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors. | 2015 Oct |
4 |